Vice President Corporate Development, AM-Pharma
Tim has 10 years of progressively responsible experience in the biotech and venture capital industries. He joined the AM-Pharma team in 2012, and is responsible for Corporate and Business Development of the company. In 2015 he co-led the $600M option-to-acquisition deal between Pfizer and AM-Pharma. Prior to AM-Pharma Tim was a senior associate at Aescap Venture, a venture capital fund investing in European medical companies, where he was instrumental in the financing and support of various portfolio companies. Tim holds an executive MBA from IMD (Switzerland), where he was named Valedictorian, and gained a Science and Innovation Masters and a Drug Innovation Masters, both with honors from Utrecht University (NL).